利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

52 条记录 (耗时 0.032 秒)

    Methods of increasing natural killer cell activity for therapy
    5.
    发明申请
    Methods of increasing natural killer cell activity for therapy 审中-公开
    增加治疗自然杀伤细胞活性的方法

    公开(公告)号：US20090042991A1

    公开(公告)日：2009-02-12

    申请号：US11918354

    申请日：2006-04-13

    申请人： James Barsoum ,  Zhenjian Du

    发明人： James Barsoum ,  Zhenjian Du

    IPC分类号： A61K31/15

    CPC分类号： A61K31/165 ,  A61K31/16 ,  Y02A50/402 ,  Y02A50/409 ,  Y02A50/415 ,  Y02A50/423 ,  Y02A50/47 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/481 ,  Y02A50/49 ,  Y02A50/491 ,  Y02A50/492

    摘要： Methods of employing bis(thio-hydrazide amides) to increase NK cell activity in a subject in need thereof, e.g., a subject with an infection or an immunodeficiency, are provided such that the disorder is not cancer, a proliferative cell disorder, a non-infective heat shock protein 70 (Hsp70) responsive disorder, or a proteasome-inhibitor responsive disorder. Typically, a subject, e.g., a human, can be in need of increased NK cell activity has an immunodeficiency or is treated for an infection (e.g., a bacterial, viral, fungal, or parasite infection, or a combination thereof). The method includes administering to the subject an effective amount of a compound represented by Structural Formula I: Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R1-R4 are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R7-R8 are independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.

    摘要翻译： 提供了使用双（硫代酰肼）酰胺来增加有需要的受试者例如具有感染或免疫缺陷的受试者的NK细胞活性的方法，使得该病症不是癌症，增殖性细胞病症， - 感染性热休克蛋白70（Hsp70）反应性病症或蛋白酶体抑制剂反应性病症。 通常，受试者（例如人）可能需要增加的NK细胞活性具有免疫缺陷或被治疗用于感染（例如细菌，病毒，真菌或寄生虫感染或其组合）。 该方法包括向受试者施用有效量的由结构式I表示的化合物：Y是共价键或任选取代的直链烃基，或Y与它们同时存在的两个> C = Z基团一起 是任选取代的芳族基团。 R 1 -R 4独立地是-H，任选取代的脂族基团，任选取代的芳基，或者R 1和R 3与它们所键合的碳原子和氮原子一起，和/或R 2和R 4与碳和 与它们键合的氮原子形成任选地与芳环稠合的非芳族杂环。 R 7 -R 8独立地为-H，任选取代的脂族基团或任选取代的芳基。 Z是O或S.